News
-
The Defense Advanced Research Projects Agency (DARPA) has awarded a $5.7 million grant to Pulmatrix for development of inhaled cationic airway lining modulator (iCALM) products to protect military personnel and civilians against airborne diseases. Read… Read more . . .
-
William M. Wells has resigned as Chairman of the Board of Valeant Pharmaceuticals and has been replaced by Robert A. Ingram. Valeant subsidiary Biovail is co-devloping the Staccato loxapine inhaler with Alexza Pharmaceuticals. The FDA… Read more . . .
-
Daiichi Sankyo subsidiary Luitpold Pharmaceuticals has acquired Roxro Pharma, which specializes in intranasal delivery of analgesics. Roxro’s lead product is Sprix ketorolac tromethamine nasal spray for short-term pain management. Sprix received FDA approval in May… Read more . . .
-
A new DPI designed for Sun Pharma by Cambridge Consultants has been on display at DDL 21. The inhaler is designed to work with carrier formulations and, according to the companies, reduces deposition in throat… Read more . . .
-
The US Court of Appeals for the DC Circuit has upheld a lower court finding that the FDA lacks the authority to regulate e-cigarettes. The agency had asserted that it had jurisdication and issued warning… Read more . . .
-
According to a study by Decision Resources, primary care physicians prefer Boehringer Ingelheim’s Spiriva to other first-line COPD treatments, with 44% surveyed saying they would increase their use of the drug in the next few… Read more . . .
-
Richmond, Virginia biopharmaceutical company Insmed Incorporated has announced a "business combination" with Transave, making Transave a wholly-owned subsidiary. The company also announced plans for Phase 3 trials of Arikace inhalation solution for the treatment of… Read more . . .
-
University of Michigan spin-off NanoBio Corporation has received its second grant for vaccine development from the Bill and Melinda Gates Foundation. The new $6 million grant is for development of an intranasal vaccine for respiratory… Read more . . .
-
According to Pearl Therapeutics, a Phase 2b study has demonstrated that its PT003 glycopyrrolate/formoterol combination MDI provides superior bronchodilation compared to placebo, compared to its individual components, and compared to tiotropium. The trial involved patients… Read more . . .
-
GlaxoSmithKline has increased its share of Theravance, with which it is developing Relovair fluticasone/vilanterol COPD product, to approximately 19%. In addition, GSK is crediting a UK "patent box" proposal to encourage R&D investments with in… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan